AstraZeneca PLC (AZN) | Common-Size Income Statement
See also
- Johnson & Johnson (JNJ), Common-Size Income Statement
- Pfizer Inc. (PFE), Common-Size Income Statement
- Novartis AG (NVS), Common-Size Income Statement
- Merck & Co. Inc. (MRK), Common-Size Income Statement
- GlaxoSmithKline PLC (GSK), Common-Size Income Statement
- Abbott Laboratories (ABT), Common-Size Income Statement
- Sanofi (SNY), Common-Size Income Statement
- Novo Nordisk A/S (NVO), Common-Size Income Statement
- UnitedHealth Group Inc. (UNH), Common-Size Income Statement
- Bristol-Myers Squibb Co. (BMY), Common-Size Income Statement
- Eli Lilly & Co. (LLY), Common-Size Income Statement
- Medtronic Inc. (MDT), Common-Size Income Statement
- Baxter International Inc. (BAX), Common-Size Income Statement
ˇ Show More
You have visited 10 password protected pages for free. Others contain data covered by 
.
Sign Up Now to get full access to whole website and cut out all advertisements.
AstraZeneca PLC, Common-Size Consolidated Income Statement
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | ||
|---|---|---|---|---|---|---|
 |
Revenue | |
|
|
|
|
|
Cost of sales | |
|
|
|
|
|
Gross profit | % |
% |
% |
% |
% |
|
Distribution costs | |
|
|
|
|
|
Research and development | |
|
|
|
|
|
Selling, general and administrative costs | |
|
|
|
|
|
Profit on disposal of subsidiary | |
|
|
|
|
|
Royalties | |
|
|
|
|
|
Net gain on disposal of property, plant and equipment | |
|
|
|
|
|
Gains on disposal of product rights | |
|
|
|
|
|
Net gain (loss) on disposal of other intangible assets | |
|
|
|
|
|
Gains on divestments of non-core products | |
|
|
|
|
|
Impairment of intangible assets relating to future licensing and contractual income | |
|
|
|
|
|
Other income | |
|
|
|
|
|
Other expense | |
|
|
|
|
|
Other operating income and expense | % |
% |
% |
% |
% |
|
Operating profit | % |
% |
% |
% |
% |
|
Returns on fixed deposits and equity securities | |
|
|
|
|
|
Returns on short-term deposits | |
|
|
|
|
|
Expected return on post-employment defined benefit plan assets | |
|
|
|
|
|
Fair value gains on debt, interest rate swaps and investments | |
|
|
|
|
|
Net exchange gains | |
|
|
|
|
|
Finance income | % |
% |
% |
% |
% |
|
Interest on debt and commercial paper | |
|
|
|
|
|
Interest on overdrafts and other financing costs | |
|
|
|
|
|
Interest on post-employment defined benefit plan liabilities | |
|
|
|
|
|
Fair value charges on debt, interest rate swaps and investments | |
|
|
|
|
|
Net exchange losses | |
|
|
|
|
|
Finance expense | % |
% |
% |
% |
% |
|
Profit before tax | % |
% |
% |
% |
% |
|
Taxation | |
|
|
|
|
|
Profit for the period | % |
% |
% |
% |
% |
|
Profit attributable to non-controlling interests | |
|
|
|
|
|
Profit attributable to owners of the Parent | % |
% |
% |
% |
% |
Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center